Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 25 mg Psilocybin Clear all

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 40
States / cities: Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions: Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 64 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psilocybin, Music Intervention
Interventions: Psilocybin (high dose), Playlist 1, Playlist 2, Playlist 3, Playlist 4, Playlist 5; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psilocybin, Neuropathy
Interventions: Psilocybin (drug), Standard of Care (SOC); Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder (AUD), PTSD
Interventions: Psilocybin 25 mg, Maltodextrin (Placebo); Drug
Lead sponsor: Nathan Brashares Sackett; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Use Disorder
Interventions: Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting; Drug
Lead sponsor: Keith Heinzerling; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Post Traumatic Stress Disorder, PTSD
Interventions: Psilocybin 25 mg; Drug
Lead sponsor: Sunstone Medical; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Psychedelic Experiences, Amnesia
Interventions: Psilocybin and Midazolam; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Phase I
Interventions: Psilocybin (Usona Institute), Inactive Placebo (Usona Institute); Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stuttering
Interventions: Psilocybin, Speech therapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: No intervention will be administered as part of this study.; Other
Lead sponsor: Usona Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lauderhill, Florida

Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions: Psilocybin, Therapeutic Support; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions: Psilocybin, Psychotherapy; Drug · Behavioral
Lead sponsor: Yvan Beaussant, MD, MSci; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Danvers, Massachusetts

Conditions: Anorexia Nervosa
Interventions: Psilocybin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Volunteers
Interventions: Psilocybin 25 mgs, TMS; Drug · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IBS - Irritable Bowel Syndrome
Interventions: Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mood (Psychological Function), Well Being, Mood, Healthy
Interventions: Psilocybin, Pimavanserin, Inactive Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

Pilot RECAP Study in Healthy Volunteers

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Psilocybin Brain Stimulation and Imaging Pilot Study

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

Psilocybin for Major Depressive Disorder (MDD)

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Open-Label Psilocybin Study in Transdiagnostic Population

Psilocybin Efficacy With or Without Pimavanserin Pretreatment